Remove In-Vivo Remove Regulation Remove RNA Remove Vaccination
article thumbnail

Using gene therapy to live longer, healthier lives

Drug Discovery World

Prolonging health span with drug development Life Biosciences aims to restore and prolong a patient’s health span by targeting the underlying biology of ageing and increasing the quality of years one spends in good health compared with just increasing the total number of years one lives.

article thumbnail

Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease

WCG Clinical

T cells and B cells — both specialized white blood cells called “lymphocytes”– represent the two arms of the adaptive immune system responsible for immune memory and recall responses to vaccines and infections. The currently approved CD-19 CAR products are autologous, ex vivo cellular therapies.

In-Vivo 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug discovery quarterly review: Second quarter 2023  

Drug Discovery World

Vaccines were up 9.1% In June 2023, AstraZeneca entered into an exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator cell therapies that have the potential to be curative in Type-1 diabetes and inflammatory bowel disease indications. billion, a decrease of $15.0

Drugs 59
article thumbnail

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

Xtalks spoke to lead author on the study, Mohamed Abdel-Mohsen, PhD, assistant professor, Vaccine & Immunotherapy Center at the Wistar Institute, about the emerging utility of identifying glycomic, or sugar, signatures on the surface of immune cells to help in their identification and potential targeting.

RNA 52
article thumbnail

How AI in pharma can live up to the hype 

Drug Discovery World

Artificial intelligence (AI) is notorious for its industry hype, touted to revolutionise the way multiple sectors operate over the next five to 10 years. Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Noel Pauli, PhD, Group Leader, Antibody Engineering, Adimab, on: ‘Harnessing in vivo diversities with a yeast-based platform for the discovery of antibodies against multi-pass membrane proteins’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59
article thumbnail

Advances in neuroscience drug discovery

Drug Discovery World

According to Medicine Discovery Catapult, these include: “Navigating the complexity of the CNS; understanding the disease pathology, and accessing predictable in vitro and in vivo cell models 2 ”. Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In In 2019, dementia accounted for 1.8

Drugs 59